KDR and renal cell carcinoma: The recently announced results of the LITESPARK-005 trial and FDA approval of belzutifan,18 which has a different mechanism of action (HIF-2 alpha inhibition) compared with VEGFR-targeted TKIs, add new uncertainty regarding the role of tivozanib in management of advanced RCC.